Publications HYPO Février2023-juillet2023

Adénomes

Pituitary tumor prognostication: WHO is really the best? Sahakian N, Dufour H, Brue T, Cuny T. Eur J Endocrinol. 2023 Jul 20;189(1):R1-R3. doi: 10.1093/ejendo/lvad080.

The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal. Villa C, Baussart B, Assié G, Raverot G, Roncaroli F.Endocr Relat Cancer. 2023 Jun22;30(8):e230021.doi:10.1530/ERC-23-0021.

Germline loss-of-function *PAM* variants are enriched in subjects with pituitary hypersecretion. Trivellin G, Daly AF, Hernández-Ramírez LC, Araldi E, Tatsi C, Dale RK, Fridell G, Mittal A, Faucz FR, Iben JR, Li T, Vitali E, Stojilkovic SS, Kamenicky P, Villa C, Baussart B, Chittiboina P, Toro C, Gahl WA, Eugster EA, Naves LA, Jaffrain-Rea ML, de Herder WW, Neggers SJ, Petrossians P, Beckers A, Lania AG, Mains RE, Eipper BA, Stratakis CA.Front Endocrinol (Lausanne). 2023 Jun 14;14:1166076. doi: 10.3389/fendo.2023.1166076. eCollection 2023.

Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?-that is the question.Trouillas J, Burman P, Losa M, McCormack A, Petersenn S, Popovic V, Theodoropoulou M, Dekkers OM, Raverot G.Eur J Endocrinol. 2023 Apr 5;188(4):C5-C8. doi: 10.1093/ejendo/lvad042.

Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas. Ilie MD, Vasiljevic A, Bertolino P, Raverot G.Endocr Rev. 2023 Mar 4;44(2):297-311. doi: 10.1210/endrev/bnac024.PMID: 36269838 Review.

Inhibition of activin signalling reduces the growth of LβT2 gonadotroph pituitary tumours in mouse. Ziverec A, Chanal M, Raymond P, Ilie MD, De Alcubierre D, Pasternack A, Ritvos O, Raverot G, Bertolino P.Endocr Relat Cancer. 2023 Feb 3;30(3):e220245. doi: 10.1530/ERC-22-0245.

Closure strategy for endoscopic pituitary surgery: Experience from 3015 patients. Baussart B, Venier A, Jouinot A, Reuter G, Gaillard S.Front Oncol. 2023 Jan 4;12:1067312. doi: 10.3389/fonc.2022.1067312. eCollection 2022.

Cushing

Pneumocystis pneumonia in patients with Cushing's syndrome: A French multicenter retrospective study. Lugat A, Lasolle H, François M, Benhenda N, Bricaire L, Cornu E, Cristante J, Gitton A, Hadoux J, Kerlan V, Le Bras M, Mezzaroba V, Puerto M, Storey C, Ouzounian S, Donadille B, **Raverot G**, Drui D, Haissaguerre M.Ann Endocrinol (Paris). 2023 Feb;84(1):37-44. doi: 10.1016/j.ando.2022.09.020.

Cushing's syndrome in the elderly: data from the European Registry on Cushing's syndrome. Amodru V, Ferriere A, Tabarin A**,** Castinetti F, Tsagarakis S, Toth M, Feelders RA, Webb SM, Reincke M, Netea-Maier R, Kastelan D, Elenkova A, Maiter D, Ragnarsson O, Santos A, Valassi E; and for the ERCUSYN Study Group.Eur J Endocrinol. 2023 Apr 5;188(4):395-406. doi: 10.1093/ejendo/lvad008.

Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France. Dormoy A, Haissaguerre M, Vitellius G, Do Cao C, Geslot A, Drui D, Lasolle H, Vieira-Pinto O, Salenave S, François M, Puerto M, Boullay HD, Mayer A, Rod A, Laurent C, Chanson P, Reznik Y, Castinetti F, Chabre O, Baudin E, Raverot G, Tabarin A, Young J.J Clin Endocrinol Metab. 2023 May 17;108(6):1475-1487. doi: 10.1210/clinem/dgac691.

Osilodrostat in Cushing's disease: The risk of delayed adrenal insufficiency should be carefully monitored. Castinetti F, Amodru V, Brue T.Clin Endocrinol (Oxf). 2023 Apr;98(4):629-630. doi: 10.1111/cen.14551. Epub 2021 Jul 22.

Déficits hypophysaires

Obesity, Overweight, and Pituitary Stalk Interruption Syndrome in Children and Young Adults. Nannette G, Bar C, Diene G, Pienkowski C, Oliver-Petit I, Jouret B, Cartault A, Porquet-Bordes V, Salles JP, Grunenwald S, Edouard T, Molinas C, Tauber M.J Clin Endocrinol Metab. 2023 Jan 17;108(2):323-330. doi: 10.1210/clinem/dgac583.

A novel *TBX19* gene mutation in patients with isolated ACTH deficiency from distinct families with a common geographical origin. Charnay T, Mougel G, Amouroux C, Gueorguieva I, Joubert F, Pertuit M, Reynaud R, Barlier A, Brue T, Saveanu A.Front Endocrinol (Lausanne). 2023 Feb 15;13:1080649. doi: 10.3389/fendo.2022.1080649. eCollection 2022.

Ataxia and Hypogonadism: a Review of the Associated Genes and Syndromes. De Michele G, Maione L, Cocozza S, Tranfa M, Pane C, Galatolo D, De Rosa A, De Michele G, Saccà F, Filla A.Cerebellum. 2023 Mar 30. doi: 10.1007/s12311-023-01549-x.

Pituitary and adrenal disorders induced by immune checkpoint inhibitors. Albarel F, Brue T, Castinetti F.Ann Endocrinol (Paris). 2023 May;84(3):339-345. doi: 10.1016/j.ando.2023.03.014. Epub Mar 23.

Oxytocin deficiency in patients with arginine vasopressin deficiency (central diabetes insipidus).Ilie MD, Raverot G.Lancet Diabetes Endocrinol. 2023 Jul;11(7):442-443. doi: 10.1016/S2213-8587(23)00126-2. Epub 2023 May 13.

Deficient anterior pituitary with common variable immune deficiency (DAVID syndrome): a new case and literature reports. Mac TT, Castinetti F, Bar C, Julia S, Pasquet M, Romanet P, Saveanu A, Mougel G, Fauquier T, Jullien N, Barlier A, Reynaud R, Brue T.J Neuroendocrinol. 2023 Jun;35(6):e13287. doi: 10.1111/jne.13287. Epub 2023 Jun 15.

Autres

Doping with testosterone and androgenic/anabolic steroids: Impact on health, screening tools and medical care. Young J.Ann Endocrinol (Paris). 2023 May;84(3):401-405. doi: 10.1016/j.ando.2023.03.025. Epub 2023 Mar 28.

Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review. Raymond P, Raverot G, Ilie MD.Endocr Relat Cancer. 2023 Mar 31;30(5):e220338. doi: 10.1530/ERC-22-0338. Print 2023 May 1.PMID: 368526.

Innovative treatments for meningiomas. Graillon T, Tabouret E, Salgues B, Horowitz T, Padovani L, Appay R, Farah K, Dufour H, Régis J, Guedj E, Barlier A, Chinot O.Rev Neurol (Paris). 2023 Jun;179(5):449-463. doi: 10.1016/j.neurol.2023.03.006. Epub 2023 Mar 21.

Immune checkpoint inhibitor-related thyroid dysfunction. Illouz F, Briet C, Rodien P. Ann Endocrinol (Paris). 2023 May;84(3):346-350. doi: 10.1016/j.ando.2023.03.005. Epub 2023 Mar 22.